1 / 26

SoGAT XX, Warsaw, Poland 12-13 June 2007 Michael Chudy, WHO; Geneva, Switzerland

Development of Biological Reference Preparations for Blood Safety-related IVDs - WHO Strategic Plan -. SoGAT XX, Warsaw, Poland 12-13 June 2007 Michael Chudy, WHO; Geneva, Switzerland. Biological Standardization.

donna-russo
Download Presentation

SoGAT XX, Warsaw, Poland 12-13 June 2007 Michael Chudy, WHO; Geneva, Switzerland

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Development of Biological Reference Preparations for Blood Safety-related IVDs - WHO Strategic Plan - SoGAT XX, Warsaw, Poland12-13 June 2007Michael Chudy, WHO; Geneva, Switzerland

  2. Biological Standardization • WHO is mandated by it's Member States to "…develop, establish and promote international standards for biological products." • In practice, biological products cover • Vaccines • Blood and blood products • Biological therapeutics • In vitro diagnostic devices

  3. Quality Assurance and Safety of Biological ProductsWHO Norms & Standards: Expert Committee on Biological Standardization Immunizations, Vaccines & Biologicals Department (IVB); Family and Community Health Cluster (FCH) Medicines, Policy and Standards Department (PSM*); Health Technology and Pharmaceuticals Cluster (HTP) (*) Expert Committee for Pharmaceutical Preparations (*)Expert Committee for Essential Medicines

  4. WHO Biological Reference Preparations • Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004)Annex 2, WHO TRS, No 932, 2005.

  5. WHO Biological Reference Preparations • International Standard [expressed in IU] • Reference Reagent • International Reference Panel • Endorsed and adopted by Expert Committee on Biological Standardization (decision making body) • Catalogue on the website www.who.int/medicines www.who.int/bloodproducts/ivd/infectious_markers

  6. Establishment ofWHO Biological Reference Preparations * *Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004); Annex 2, WHO TRS, No 932, 2005.

  7. WHO Biological Reference Preparations:IVD Strategic Plan (5 years) For blood safety-related IVDs: • Serological test platforms • NAT assays • Other tests Meeting of the WHO Collaborating Centres for Biological Standards and Standardization (NIBSC, CBER, PEI) in Jan 2007 organized by WHO QSD/PSM

  8. Meeting of WHO Collaborating Centres forBiological Standards and Standardization • WHO Biological Reference Preparations: Review of current situation and new proposals • Role of epidemiological data worldwide • New test platforms and emerging technologies • Define priority projects • Ways forward for collaboration (WHO CC-Network model) • Would strengthen the collaboration between the WHO CCs, and between WHO CCs and WHO • Respect interests of CCs • Synergize activities

  9. WHO Biological Reference Preparations:Current Situation and Proposals Pathogens with impact on blood safety • HIV • HBV , HCV • Other hepatitis viruses • B19V , HTLV1/2, CMV • Bacteria and parasites (causative agents for syphilis, malaria, Chagas disease) • Arthropod-borne agents (WNV, dengue virus) • Prion agents • Other blood-borne agents (bacteria, leishmania, HHV-8) √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ NAT; √ Serology; √ Other

  10. Testing for Syphilitic Infection • Treponema pallidum • Blood screening test in many countries • Anti-syphilitic serum, WHO 1st IS (#HS) nearly exhausted • Proposal for replacement: • IgG preparation (plasma pool of samples from latent syphilis patients) • IgM/IgG preparation (plasma pool of samples from acute syphilis patients) • Collaborative study is completed • Report to ECBS in October 2007

  11. Testing for Malarial Infection • Plasmodium falciparum, P. malariae, P. ovale, P. vivax • Endemic in more than 100 countries • Donor testing to reduce the deferral period/loss of donors (non-endemic areas) • Direct parasite detection • Giemsa- or Wright's-stained thick and thin blood film (gold standard method) • Time expensive, need experienced hands • Antigen detection • No sufficient sensitivity • NAT testing • Pro and cons (e. g. DNA vs RNA!) • Antibody testing • Effective indicator of infection • Negative result no guarantee that donor is not infected 1st IS P. falciparum DNA, #04/176 (ECBS 2006) Antibody Reference Panel (proposal)

  12. Chagas Disease • American Trypanosomiasis • Protozoan parasite Trypanosoma (T.) cruzi • First described by Carlos Chagas in 1909 • Morphologically distinct stages • Insect-stage: epimastigote • Host-stage: Trypomastigote/amastigote • >100 strains classified into two groups (T. cruzi I and T. cruzi II) • Chronic asymptomatic carrier state in infected individuals • Endemic in Latin America • Non-endemic areas: issue due to emigration (e.g. USA, Spain, France) • 16–18 million infected cases; >80 million people at risk • T. cruzi DNA detected in mummies from Chile and Peru (7050 BC-1050 AD)

  13. T. cruzi Infection Main routes of parasite transmission • By bloodfeeding bugs (sub-family Triatominae); the faeces of the insects contain parasites which can enter the wound left after the bloodmeal, usually when it is scratched or rubbed • Transfusion with infected blood (whole blood and components); • Tissue and organ transplantations • Congenital (from infected mother to fetus)

  14. Testing for T. cruzi Infection • Diagnosis is complex due to low parasitemia in later stages • Microscopic examination of T. cruzi in blood, lymph fluid, cerebrospinal fluid • Xenodiagnosis (uninfected bugs are fed on an individual suspected of having the disease; investigation of blood smear microscopically several weeks later) • PCR (limited sensitivity due to low T.cruzi level in chronic stages) • Serological tests detecting antibodies are well-suited

  15. Testing for T. cruzi Infection:Serological Tests for Detecting Antibodies • Screening tests (initial tests) • Indirect hemagglutination assay (IHA) • Enzyme-linked immunosorbent assay (ELISA) • Confirmatory tests (supplemental tests) • Indirect immunoflourescence assay (IFA) • Radio-immuno-precipitation assay (RIPA) • Immunoblot/Western blot • Rapid tests Antigens used for ELISA tests • Whole parasite lysates or semipurified antigenic fractions (epimastigote stage) • Trypomastigote excretory-secretory antigens (TESAs; major component trans-sialidase) • Cocktail of recombinant proteins • Synthetic peptides

  16. Testing for T. cruzi Infection:Blood Donation Screening • Endemic areas • In most counties for more than 10 years • Prevalence of T. cruzi-infected blood is higher than of HIV, HBV and HCV • Transfusion-transmitted rest-risk differs from country to country • Non-endemic areas • USA • >12 million immigrants from endemic regions • ARC pilot studies since end of Jan 2007 with ORTHO test • Spain • Recommendation to test donors from endemic regions (not for excl. source plasma) • To reduce the deferral period/loss of donors • France • Evaluation of screening tests (blood centre in Tours)

  17. Testing for T. cruzi Infection • Problems with serological tests • Indeterminate results and false-positive results • Other T. spec • Other infectious diseases: e.g. leishmaniasis, malaria, syphilis • Autoimmune disorders • Lack of sensitivity of some assays • No global reference materials for serological tests available • Need for establishing of appropriate BRPs/already ECBS endorsed • WHO Consultation on 2-3 July 2007, WHO/HQ Geneva • Reference Preparations for both screening and clinical diagnostics

  18. Epidemiological InformationWHO Collaborating Centres' Meeting (29-30 January 2007) Points for discussion • Changes of prevalence data of infectious agents (variability, new variants, mutants) • Emerging/re-emerging agents: investigation to assess the relevance on blood and blood product safety • Coordination and information exchange between the WHO CCs and with other groups (e.g. WP-TTID/ISBT)

  19. New Tests and Emerging TechnologiesWHO Collaborating Centres' Meeting (29-30 January 2007) • New generations of ELISA systems/platforms • New NAT approaches • Emerging technologies: • Chip technology (microarray) • Nanotechnology-based assays • Suitability of existing WHO Biological Reference Preparations

  20. Priority Projects for Biological Reference Preparations WHO Collaborating Centres' Meeting (29-30 January 2007) Consultation Feasibility studies Collaborative study *IS **Panel 1two panels for HBsAg- and NAT-tests;

  21. Future Projects for Biological Reference Preparations WHO Collaborating Centres' Meeting (29-30 January 2007) • New proposals (ECBS endorsement is needed): • Anti-HTLV-1/2 antibody panel • Anti-Plasmodium species antibody panel • For further discussion: • HIV-2 genotype panel • HCV genotype panel • B19V genotype panel • Anti-CMV antibody standard • WNV RNA preparation/pan panel for arthropod-borne flaviviruses RNA • HCV core antigen preparation • Preparations for anti-HHV-8 antibodies and HHV-8 DNA • TSE blood preparations • Blood-borne bacteria panel • Anti-Leishmania antibody panel

  22. Ways Forward for CollaborationWHO Collaborating Centres' Meeting (29-30 January 2007) • To monitor progress • Annual face-to-face meetings • Teleconferences • Need to establish a network of WHO CCs for IVD-related biological standardization representing all the WHO Regions • To ensure complementary and focused expertise at global level • Master form sheet for future BRP proposals

  23. Meeting of WHO Collaborating Centres forBiological Standards and Standardization Meeting Report:Development of WHO Biological Reference Preparations for blood safety-related in vitro diagnostic tests Shortly on the website:www.who.int/bloodproducts/ivd/infectious_markers

  24. WHO Biological Reference Preparations • Validation, quality control and comparability of IVD tests(analytical sensitivity) • Tool for identifying unsuitable diagnostic kits • Tool for global regulation and harmonization in the IVD area • Tool for regulatory bodies, manufacturers, product users (physicians/scientists) to communicate in a "common language" • Underpin the appropriate diagnoses of the disease

  25. WHO Collaborating Centres for Biological Standards and Standardization • WHO CCs: NIBSC, CBER, PEI • WHO CCs represent the greatest know how and experience in establishing global measurement standards • Characterization of source materials • Freeze-drying procedure • Organizing collaborative studies • Custodian/distribution of reference materials • In collaboration with manufacturers, regulatory bodies, blood transfusion services, WHO CCs involved in diagnostics of blood-borne infections, scientific experts,…

More Related